These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28129026)

  • 1. A systematic review of health economic evaluations of vaccines in Brazil.
    Sartori AMC; Rozman LM; Decimoni TC; Leandro R; Novaes HMD; de Soárez PC
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-12. PubMed ID: 28129026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines are different: A systematic review of budget impact analyses of vaccines.
    Loze PM; Nasciben LB; Sartori AMC; Itria A; Novaes HMD; de Soárez PC
    Vaccine; 2017 May; 35(21):2781-2793. PubMed ID: 28427846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
    Andrus JK; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161
    [No Abstract]   [Full Text] [Related]  

  • 4. Perspectives on the development and use of economic evidence for immunization decision-making in a developing country.
    Molina-Aguilera IB
    Vaccine; 2015 May; 33 Suppl 1():A6-7. PubMed ID: 25919176
    [No Abstract]   [Full Text] [Related]  

  • 5. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.
    Jauregui B; Janusz CB; Clark AD; Sinha A; Garcia AG; Resch S; Toscano CM; Sanderson C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1():A21-7. PubMed ID: 25919164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of health economic evaluation studies of dengue vaccines.
    de Soárez PC; Silva AB; Randi BA; Azevedo LM; Novaes HMD; Sartori AMC
    Vaccine; 2019 Apr; 37(17):2298-2310. PubMed ID: 30910406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Foreword.
    Etienne CF
    Vaccine; 2015 May; 33 Suppl 1():A1. PubMed ID: 25919148
    [No Abstract]   [Full Text] [Related]  

  • 8. Gavi's balancing act: Accelerating access to vaccines while ensuring robust national decision-making for sustainable programmes.
    Sosler S; Kallenberg J; Johnson HL
    Vaccine; 2015 May; 33 Suppl 1():A4-5. PubMed ID: 25919172
    [No Abstract]   [Full Text] [Related]  

  • 9. Systematic review of economic evaluations of vaccination programs in mainland China: Are they sufficient to inform decision making?
    Pan XF; Griffiths UK; Pennington M; Yu H; Jit M
    Vaccine; 2015 Nov; 33(46):6164-72. PubMed ID: 26435189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ProVac initiative and evolving decision support.
    Sanderson CF
    Vaccine; 2015 May; 33 Suppl 1():A8-10. PubMed ID: 25919181
    [No Abstract]   [Full Text] [Related]  

  • 11. Systematic review of economic evaluation studies: are vaccination programs efficient in Spain?
    García-Altés A
    Vaccine; 2013 Mar; 31(13):1656-65. PubMed ID: 23370153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.
    Cortés I; Pérez-Camarero S; Del Llano J; Peña LM; Hidalgo-Vega A
    Vaccine; 2013 Aug; 31(35):3473-84. PubMed ID: 23764534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of vaccines in Canada: A systematic review.
    Chit A; Lee JK; Shim M; Nguyen VH; Grootendorst P; Wu J; Van Exan R; Langley JM
    Hum Vaccin Immunother; 2016 May; 12(5):1257-64. PubMed ID: 26890128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valuing vaccines: deficiencies and remedies.
    Bloom DE
    Vaccine; 2015 Jun; 33 Suppl 2():B29-33. PubMed ID: 26022563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review.
    Wong CKH; Liao Q; Guo VYW; Xin Y; Lam CLK
    Vaccine; 2017 May; 35(24):3153-3161. PubMed ID: 28476628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contributions from the systematic review of economic evaluations: the case of childhood hepatitis A vaccination in Brazil.
    De Soárez PC; Sartori AM; Santos A; Itria A; Novaes HM; Martelli CM
    Cad Saude Publica; 2012 Feb; 28(2):211-28. PubMed ID: 22334390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
    Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review.
    Herdman M; Cole A; Hoyle CK; Coles V; Carroll S; Devlin N
    Value Health; 2016; 19(2):255-66. PubMed ID: 27021761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of health economic analyses in vaccine decision making.
    Black S
    Vaccine; 2013 Dec; 31(51):6046-9. PubMed ID: 23968768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stakeholders' perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study.
    van der Putten IM; Evers SM; Deogaonkar R; Jit M; Hutubessy RC
    BMC Public Health; 2015 Apr; 15():356. PubMed ID: 25881178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.